Vaccine Advisory Panel Recommends Expanded RSV Use, And Two New Vaccines

A recent meeting of the Advisory Committee on Immunization Practices (ACIP) recommended expanding the use of RSV vaccines for adults aged 50-59, especially those at high risk of severe illness. If accepted by the CDC, this move would make the vaccines, including those from GSK and Pfizer, more accessible, with insurance coverage for eligible individuals.

Additionally, ACIP recommended a new meningococcal vaccine, a chikungunya vaccine for travelers, and adjustments to previous recommendations on chikungunya vaccines. The committee also highlighted potential risks, such as Guillain-Barré syndrome, associated with some RSV vaccines, though the overall goal is to enhance public health protection. Read more from STAT News here.